SCREEN-HFL (SCReening Evaluation of the Evolution of New Heart Failure) - a Longitudinal Study (SHF-L)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01581827|
Recruitment Status : Completed
First Posted : April 20, 2012
Last Update Posted : April 9, 2018
Heart failure (when the heart does not pump as well as it used to) is a medical condition which reduces the quality of life for the sufferers. Approximately 10% of people in western societies aged over 75 develop heart failure. There has been a shift towards prevention of this disease and it is hoped that BNP (brain natriuretic peptides) and NT-proBNP (N-terminal proBNP) will prove to be useful indicators of those at greatest risk. The current study therefore plans to follow up the 3500 participants at risk of heart failure from the original SCREEN-HF study.
Participants who are willing to participate will be contacted annually. They will undergo a short physical exam, will be asked to complete a Quality of Life questionnaire and will have a blood sample taken. At the end of the study participants will also have an ECG and an echocardiogram.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||3000 participants|
|Official Title:||SCREEN-HFL (SCReening Evaluation of the Evolution of New Heart Failure) - a Longitudinal Study|
|Study Start Date :||January 2009|
|Actual Primary Completion Date :||December 2015|
|Actual Study Completion Date :||December 2017|
People at high risk of heart failure (from SCREEN-HF study)
- Change in NT-proBNP [ Time Frame: baseline and 5 years ]
- Change in echocardiogram [ Time Frame: baseline and 5 years ]
- incidence of new heart failure [ Time Frame: baseline and 5 years ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01581827
|Caulfield, Victoria, Australia, 3162|
|Principal Investigator:||Henry Krum, MBBS FRACP PhD||Monash University/Alfred Hospital|